Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $29
Morgan Stanley analyst Tejas Savant maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and lowers the price target from $32 to $29.
Comfort Systems, Gannett, CommScope And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded slightly lower, with the Dow Jones dropping around 30 points on Thursday. Here are some big stocks recording gains in today’s session.
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell
• Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's trading, 138 companies set new 52-week lows.
6 Analysts Have This to Say About Maravai LifeSciences
Over the past 3 months, 6 analysts have published their opinion on Maravai LifeSciences (NASDAQ:MRVI) stock. These analysts…
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows.
Where Maravai LifeSciences Stands With Analysts
Analysts have provided the following ratings for Maravai LifeSciences (NASDAQ:MRVI) within the last quarter:
What 6 Analyst Ratings Have To Say About Maravai LifeSciences
Within the last quarter, Maravai LifeSciences (NASDAQ:MRVI) has observed the following analyst ratings:
Goldman Sachs Maintains Buy on Maravai LifeSciences, Lowers Price Target to $18
Goldman Sachs analyst Matthew Sykes maintains Maravai LifeSciences (NASDAQ:MRVI) with a Buy and lowers the price target from $30 to $18.
Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $32
Morgan Stanley analyst Tejas Savant maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and lowers the price target from $35 to $32.